1. Front Med (Lausanne). 2022 Jan 14;8:788869. doi: 10.3389/fmed.2021.788869. 
eCollection 2021.

Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of 
Pancreatic Ductal Adenocarcinoma.

Osei-Bordom DC(1)(2)(3), Sachdeva G(2), Christou N(1)(4)(5).

Author information:
(1)Department of General Surgery, Queen Elizabeth Hospital, University Hospitals 
Birmingham, Birmingham, United Kingdom.
(2)Institute of Immunology and Immunotherapy, University of Birmingham, 
Birmingham, United Kingdom.
(3)National Institute for Health Research (NIHR) Birmingham Biomedical Research 
Centre, Centre for Liver and Gastroenterology Research, University of 
Birmingham, Birmingham, United Kingdom.
(4)Department of General Surgery, University Hospital of Limoges, Limoges, 
France.
(5)EA3842 CAPTuR Laboratory "Cell Activation Control, Tumor Progression and 
Therapeutic Resistance", Faculty of Medicine, Limoges, France.

Pancreatic ductal adenocarcinomas (PDAC) represent one of the deadliest cancers 
worldwide. Survival is still low due to diagnosis at an advanced stage and 
resistance to treatment. Herein, we review the main types of liquid biopsy able 
to help in both prognosis and adaptation of treatments.

Copyright Â© 2022 Osei-Bordom, Sachdeva and Christou.

DOI: 10.3389/fmed.2021.788869
PMCID: PMC8795626
PMID: 35096878

Conflict of interest statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.